Compare Rocket Lab USA Inc (RKLB) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs Stryker Corporation — how do they compare? Rocket Lab USA Inc trades at $68.21 (market cap $43.74B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 2.4× Rocket Lab USA Inc's market cap, and Stryker Corporation pays a 1.27% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Lab USA Inc for 29 Days and Stryker Corporation for 21 Days on average.
| RKLB | SYK | |
|---|---|---|
Market Cap | $43.74B | $106.24B |
Volume | 22,892,581 | 2,982,001 |
Sector | Industrials | Health |
52-Week High | $150.23 | $388.35 |
52-Week Low | $39.48 | $269.75 |
Typical Hold Time | 29 Days | 21 Days |
Enterprise Value | $41.57B | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $68.21, down 5.16% today, amid a bearish technical signal despite recent positive business developments. The company secured its largest-ever commercial Electron deal with Synspective for 20 launches, boosting its backlog past 100 missions. However, financials show negative profitability with a net income margin of -21.51% and elevated valuation ratios including P/S of 51.96. Technical indicators show bearish momentum with key support at $64.
The outlook remains mixed with strong analyst bullishness (76% buy ratings, $107 consensus target) contrasting with fundamental challenges. Investment opportunity lies in execution of the growing launch backlog and Neutron rocket development, while risks include sustained losses, SpaceX competition, and high valuation multiples requiring significant future growth to justify.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
